Elekta: New Clarity Soft Tissue Visualization Software Neutralizes Organ Motion Challenges During Prostate Cancer Radiotherapy  
12/17/2012 9:58:38 AM

STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: Elekta has received 510(k) clearance for its Clarity® 4D Monitoring software, enabling U.S. medical centers to implement this new way of reducing the uncertainty caused by prostate motion during radiation treatment. Physicians will be able to monitor the motion of the prostate and surrounding tissues and organs – in real-time and with sub-millimeter accuracy – during the delivery of therapeutic radiation beams. The ability to continuously visualize the prostate’s precise location constantly during treatment is especially important for clinicians pursuing advanced prostate protocols, such as reduced margin hypofractionated therapy or advanced stereotactic ablative body radiotherapy (SABR). “What makes 4D monitoring with Clarity a possible ‘game-changer’ is that it’s simple, inexpensive, and will enable real time continuous monitoring of the prostate – increasingly critical as we consider techniques such as hypofractionation, which entails treating patients in shorter therapy courses, but with longer individual treatments,” says James Wallace, MD, radiation oncologist at Fletcher Allen Health Care (Burlington, VT, US). “We know that the prostate moves during these prolonged treatments and we are going to have to account for it in some way. The capability to observe the prostate from the beginning of the fraction to the end will be incredibly powerful. We will integrate 4D monitoring with Clarity into our clinical practice as soon as we can.”